Clinical efficacy and compliance of sublingual immunotherapy with <i><scp>D</scp>ermatophagoides farinae</i> drops in patients with atopic dermatitis

Qin, Ying; Mao, Jing-Ran; Sang, Yue-chan; Li, Wenxiu

doi:10.1111/ijd.12302

Cited by 42 publications

(60 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…was similar; the dose of D.f. in the study by Qin et al [21] was approximately 100 times greater than that in the other studies ( Table 2).…”

Section: Resultsmentioning

confidence: 53%

“…In the study by Pajno et al [20••], there was no significant difference in the treatment versus the control group in visual analog scale (VAS) scores, but there was a trend toward an increase in the VAS score in the control group and a decrease in the treatment group at the end of the study. In the study by Qin et al [21], VAS scores decreased significantly in the treatment group compared to the control group.…”

Section: Resultsmentioning

confidence: 84%

“…In one study [19], total IgE serum levels and specific IgE levels were significantly reduced after 1 year of SLIT treatment. In another study [21], the treatment group had significantly higher D. farinae-specific IgG4 levels at 6 and 12 months of treatment.…”

Section: Resultsmentioning

confidence: 86%

“…In one study [20••], the change in SCORAD significantly improved from month 9 in subjects with mild-moderate atopic dermatitis (SCORAD <40), whereas there was no significant change in subjects with severe atopic dermatitis (SCORAD >40). Two studies [18,21] did not include cases of severe atopic dermatitis and one study [17] did not categorize enrolled subjects by severity. Although the study by Cadario et al [19] included nine subjects (10 %) with severe atopic dermatitis (SCORAD >60), the authors did not stratify the results based on mild-moderate versus severe atopic dermatitis.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Sublingual Immunotherapy in the Treatment of Atopic Dermatitis: a Systematic Review Using the GRADE System

Gendelman

Lang

2014

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Controversy exists regarding the role of allergen immunotherapy as a therapeutic intervention for patients with atopic dermatitis and aeroallergen sensitivity. Our aim was to critically appraise the evidence supporting the use of sublingual immunotherapy for patients with atopic dermatitis and aeroallergen sensitivity. We performed a literature search using the terms "sublingual immunotherapy" and "atopic dermatitis" and "sublingual immunotherapy" and "eczema." We used the same terms to search PubMed, Ovid, and Scopus. Our limits were "Humans" and "English." We excluded articles that were not in English. These articles were analyzed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Many studies reported improvement in clinical symptoms of atopic dermatitis. Serious methodological shortcomings were noted including but not limited to lack of control group, lack of randomization, incomplete descriptions of randomization and/or allocation concealment, many enrolled subjects not completing participation, and/or data analysis not by intention to treat.

show abstract

“…was similar; the dose of D.f. in the study by Qin et al [21] was approximately 100 times greater than that in the other studies ( Table 2).…”

Section: Resultsmentioning

confidence: 53%

Section: Resultsmentioning

confidence: 84%

Section: Resultsmentioning

confidence: 86%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sublingual Immunotherapy in the Treatment of Atopic Dermatitis: a Systematic Review Using the GRADE System

Gendelman

Lang

2014

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…A 45% decrease was described for the active group in a vehicle controlled study using patients with rhinoconjunctivitis [30] and 46% reduction of clinical scores was reported in an open non-controlled trial in patients with AD sensitive to dust mites [31] after one year of SLIT. Some of the published studies also report on the decreased need for rescue medications [32]. A significant (*) increase was found at the end of the study for both the SLIT and the control group (p<.0001).…”

Section: Discussionmentioning

confidence: 92%

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

K¹

2013

J Allergy Ther

View full text Add to dashboard Cite

Sublingual Allergen Specific Immunotherapy (SLIT) has been advocated for the treatment for allergies. Controlled studies are difficult to perform in humans due to the variety of allergies, diet, and allergenic exposure. This prospective, randomized, controlled study evaluated clinical and immunological effects of one year of SLIT using an experimental model of atopic dermatitis in dogs. Eighteen Beagles, sensitized to dust mites, timothy grass and ragweed were divided into control (n=6, vehicle) and active (n=12, 3 allergens) groups. Allergen challenge and scoring of clinical signs was done before and at the end of one year of SLIT. Blood was drawn at baseline, 4,8, and 12 months of SLIT and 2 months after stopping SLIT to measure allergen-specific IgE, IL-10, and TGF-beta.After 12 months of SLIT, ANOVA showed significant decrease of clinical scores for both groups (p<.0001) but no significant differences between groups. T tests within each group comparing pre vs. post treatment scores showed statistically significant decrease in the control (p=0.042) and in the SLIT group (p=0.00027). Effect size using Cohen's d was 1.182 for control and 2.1 for allergen group. Thus, decrease from baseline to post-treatment was nearly twice as large in the allergen as in the control group.Mixed results were found for allergen-specific IgE with significant decrease for dust mites (p=0.0242) and increase for ragweed (p=0.0074) at the end of the study. SLIT induced significant increase of TGF-beta (p=0.03) and IL-10 (p=0.0009) after ragweed stimulation compared to baseline and to the control group. TGF-beta increase abated after SLIT discontinuation results consistent with SLIT induced T regulatory response. Interestingly a significant increase for IL-10 after timothy stimulation was seen for both groups at the end of study (p<.0001).It is concluded that this experimental model is useful to investigate treatments for atopic dermatitis and their immunologic effects.

show abstract

Specific allergen immunotherapy for the treatment of atopic eczema

Tam

Calderón

Manikam

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Comparison 1 Immunotherapy versus control, Outcome 6 Use of other medications for eczema.. .. Analysis 2.1. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 1 Participant-or parentreported specific symptoms of eczema-SCORAD part C by route of immunotherapy.. .. .. .. .. Analysis 2.2. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 2 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by route of immunotherapy.. .. .. Analysis 2.3. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 3 Participant-or parentreported specific symptoms of eczema-SCORAD part C by allergen type.. .. .. .. .. .. .. Analysis 2.4. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 4 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by allergen type.. .. .. .. .. Analysis 2.5. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 5 Participant-or parentreported specific symptoms of eczema-SCORAD part C by participant age.. .. .. .. .. .. . Analysis 2.6. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 6 Participant-or parentreported specific symptoms of eczema-itch severity by participant age.. .. .. .. .. .. .. . Analysis 2.7. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 7 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by participant age.. .. .. .. . Analysis 2.8. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 8 Participant-or parentreported specific symptoms of eczema-itch severity by severity at randomisation.. .. .. .. .. . Analysis 2.9. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 9 Participant-or parentreported specific symptoms of eczema-severity of sleep disturbance by severity at randomisation.. .. .. Analysis 2.10. Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 10 Adverse events: any local reaction by route of immunotherapy.

show abstract

Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis

Cited by 42 publications

References 25 publications

Sublingual Immunotherapy in the Treatment of Atopic Dermatitis: a Systematic Review Using the GRADE System

Sublingual Immunotherapy in the Treatment of Atopic Dermatitis: a Systematic Review Using the GRADE System

Clinical and Immunologic Effects of Allergen-Specific Sublingual Immunotherapy in a Canine Model of Atopic Dermatitis: A Double Blind, Randomized, Controlled Study

Specific allergen immunotherapy for the treatment of atopic eczema

Contact Info

Product

Resources

About